Jacob Basilius, MD
Urology · Orange, CANPI 1043741911
Payments from drug & device makers
What this record shows
11 manufacturers reported payments, led by Intuitive Surgical at 52.8% of the total. Reporting peaked in 2023 at $3,000 and has fallen 86.2% since, to $414 in 2025.
Across 100 payments — averaging $56.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Boston Scientific$2K
- Procept Biorobotics Corporation$308
- Teleflex LLC$223
- Endo Pharmaceuticals Inc.$122
- Laborie Medical Technologies Corp.$120
- plus $255 from 5 others
What the payments were for
- Food & beverage$2,68047%
- Education$3,00053%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 1 | $3,000 |
| Boston Scientific | 81 | $1,652 |
| Procept Biorobotics Corporation | 5 | $308 |
| Teleflex LLC | 5 | $223 |
| Endo Pharmaceuticals Inc. | 1 | $122 |
| Laborie Medical Technologies Corp. | 1 | $120 |
| Ambu Inc. | 2 | $103 |
| Olympus Corporation Of The Americas | 1 | $61 |
| Valencia Technologies Corporation | 1 | $58 |
| 180 Medical, Inc. | 1 | $18 |
| Axonics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$3,000
- UroLift$153
- XIAFLEX$122
- Optilume BPH Drug Coated Balloon Catheter$120
- LithoVue$113
- TACTRA$111
- Flexible Probe$107
- GENERAL KIDNEY STONE DISEASE$101
How this compares
$5,680 in reported general payments places this provider in the 65th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Solifenacin Succinate | 44 | $796 |
| Trospium Chloride | 32 | $771 |
| Tamsulosin Hcl | 92 | $697 |
| Finasteride | 21 | $293 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 63 | $227 |
| Oxybutynin Chloride | 30 | $186 |
| Ciprofloxacin Hcl | 18 | $70 |
| Oxycodone Hcl | 21 | $44 |
| Meloxicam | 13 | $32 |
Paid to pharmacies, not to this prescriber.
Other urology in Orange
- Edward UchioOrange$849K
- Jaime LandmanOrange$657K
- Ralph ClaymanOrange$523K
- Faysal YafiOrange$335K
- Bela DenesOrange$235K
- Stephen FreedlandWest Hollywood$1.9M
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Steven WilsonIndio$1.1M
- Stuart HoldenLos Angeles$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.